Abstract
Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins. These enzymes participate in and regulate vital processes such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling, and cell survival. Dysregulation of RTKs contributes to the development of different types of tumors. RTKs deregulation in different types of cancer has been reported for more than 30 RTKs. Due to their critical roles, the specific targeting of RTKs in malignancies is a promising approach. Targeted cellular and molecular therapies (personalized medicine) have been known as new types of therapeutics, which prevent tumor cell proliferation and invasion by interfering with molecules essential for tumor growth and survival. Specific targeting of RTKs using monoclonal antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The growing number of mAbs approved by the authorities implies on the increasing attentions and applications of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances that target RTKs expressed on the tumor cell surface. In this communication, we review the recent progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
Keywords: Cancer, monoclonal antibody, receptor tyrosine kinase, targeted therapy.
Current Drug Targets
Title:Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Volume: 17 Issue: 14
Author(s): Mahdi Shabani and Mohammad Hojjat-Farsangi
Affiliation:
Keywords: Cancer, monoclonal antibody, receptor tyrosine kinase, targeted therapy.
Abstract: Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins. These enzymes participate in and regulate vital processes such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling, and cell survival. Dysregulation of RTKs contributes to the development of different types of tumors. RTKs deregulation in different types of cancer has been reported for more than 30 RTKs. Due to their critical roles, the specific targeting of RTKs in malignancies is a promising approach. Targeted cellular and molecular therapies (personalized medicine) have been known as new types of therapeutics, which prevent tumor cell proliferation and invasion by interfering with molecules essential for tumor growth and survival. Specific targeting of RTKs using monoclonal antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The growing number of mAbs approved by the authorities implies on the increasing attentions and applications of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances that target RTKs expressed on the tumor cell surface. In this communication, we review the recent progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
Export Options
About this article
Cite this article as:
Shabani Mahdi and Hojjat-Farsangi Mohammad, Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy, Current Drug Targets 2016; 17 (14) . https://dx.doi.org/10.2174/1389450116666151001104133
DOI https://dx.doi.org/10.2174/1389450116666151001104133 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues
Current Vascular Pharmacology Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Is it Necessary to Calculate Young’s Modulus in AFM Nanoindentation Experiments Regarding Biological Samples?
Micro and Nanosystems Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals
Current Topics in Medicinal Chemistry Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging How does the Selection of Laboratory Mice Affect the Results of Physiological Distribution of Radiopharmaceuticals?
Current Radiopharmaceuticals Retinoids in Clinical Use
Medicinal Chemistry Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synthetic Approaches to Heterocyclic Guanidines with Biological Activity: An Update
Current Organic Chemistry Crotamine, a Small Basic Polypeptide Myotoxin from Rattlesnake Venom with Cell-Penetrating Properties
Current Pharmaceutical Design Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Molecular Symmetry: A Structural Property Frequently Present in New Cytotoxic and Proapoptotic Drugs
Mini-Reviews in Medicinal Chemistry